Please login to the form below

Not currently logged in
Email:
Password:

niraparib

This page shows the latest niraparib news and features for those working in and with pharma, biotech and healthcare.

Lynparza cleared for first-line ovarian cancer use in China

Lynparza cleared for first-line ovarian cancer use in China

GlaxoSmithKline. GSK’s rival drug Zejula (niraparib) is also closing in on the first-line ovarian cancer setting – it recently presented positive findings in this indication at the European Society of

Latest news

More from news
Approximately 4 fully matching, plus 33 partially matching documents found.

Latest Intelligence

  • Deal Watch April 2016 Deal Watch April 2016

    Licensing one indication for a new product is unusual not least of all because of potential pricing issues if niraparib is launched by different companies at different prices. ... 500. Tesaro (US). Janssen (US). License and collaboration. Niraparib PARP

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Language barriers: Obesity has become a loaded word
...
Spotlight interview: 15 minutes on digital in medical communications
Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications...
Generating data on long-term outcomes with gene and other advanced therapies
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’....

Infographics